This bill directs the Secretary of Defense to set up a named pilot program to evaluate and accelerate diagnostic technologies that help detect traumatic brain injury (TBI) in members of the Armed Forces. It tasks the Department with studying how such technologies perform in operational contexts, how they integrate with existing diagnostics and care pathways, and how to move validated tools from prototype to production.
For medical officers, readiness planners, and defense contractors, the bill matters because it creates a formal channel for DOD to fund R&D, test devices in military-relevant settings, and consider adoption. If the pilot works, the Department could change screening and triage at point of injury, affecting clinical practice, deployment medical kits, procurement choices, and the market for TBI diagnostics.
At a Glance
What It Does
The bill requires the Secretary of Defense, through the Assistant Secretary for Health Affairs, to establish a pilot program — the "Warfighter Traumatic Brain Injury Diagnostics Project" — to assess, test, and help transition devices that assist clinicians in diagnosing TBI. The pilot can run research studies, incentivize military and civilian trauma site participation, and award grants to eligible U.S. entities working on covered diagnostic technologies.
Who It Affects
Affected parties include Department of Defense medical providers and combatant commands, military medical treatment facilities and Special Operations units, civilian level-one trauma centers, diagnostic developers (including nontraditional defense contractors), and the national technology and industrial base that supports medical manufacturing.
Why It Matters
The pilot creates an explicit DOD pathway to vet and transition acute TBI diagnostics into operational use — an intersection of clinical validation, procurement, and production policy that could shorten the path for promising technologies to reach deployed forces and influence private-sector investment decisions.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill instructs the Secretary of Defense to stand up a named pilot program that focuses on technologies that aid clinicians in diagnosing traumatic brain injury. The program has three core aims: (1) assess feasibility of supporting eligible entities working on candidate diagnostics that the Department might procure and use in operational deployments; (2) carry out studies to evaluate how those technologies distinguish between mild, moderate, and severe TBI and how they combine with other diagnostic tools or sensors; and (3) help transition validated technologies from prototype to production, including addressing manufacturing barriers.
Operationally, the statute envisions mixed teams running the studies: DOD trauma, primary care, and TBI experts; DOD emergency medical technicians; affected service members; and technical staff knowledgeable about the assessed technologies. The pilot will also actively recruit participation from military medical facilities, Special Operations units, and civilian level-one trauma centers, and the Secretary may use incentives to secure that participation.
The bill authorizes grant awards to eligible U.S.-organized entities, with the grants restricted to activities such as validation testing, prototyping, solving production problems, supplying commercially available diagnostics for DOD testing, and building industry relationships that bring nontraditional suppliers into DOD problem sets.Practical guardrails are embedded: Congress authorizes appropriations for the program across multiple fiscal years and sets an end date for the authority; the Secretary must report the pilot’s results and recommend whether the Department should procure additional diagnostics and what further steps or legislative changes might be needed. The statute also defines covered terms (for example, what counts as a covered diagnostic technology and who qualifies as an eligible entity) so that grant competition and program participation are limited to entities with clear U.S. ties or ownership structures.The bill is not a procurement order; it builds an evidence and production pathway.
It centers on acute and point-of-injury diagnostics and emphasizes integration with imaging, blood biomarkers, electrophysiology, oculomotor tracking, and environmental sensors. The Department’s decisions on funding, site selection, and award preferences will shape which technologies get real-world testing and which firms gain the credibility necessary for larger-scale adoption.
The Five Things You Need to Know
The Secretary must establish the pilot program within 180 days after the bill becomes law.
Congress authorizes $5,000,000 per year for fiscal years 2026 through 2029 to carry out the pilot.
The program’s authority terminates on September 30, 2029.
The Secretary must submit a report to the congressional defense committees within 90 days after the program ends that summarizes results and says whether the Department should procure additional covered diagnostics and what legislative steps may be needed.
Grant awards must prioritize entities with demonstrated histories in relevant diagnostics or ties to the national technology and industrial base and may be used for validation testing, addressing manufacturing challenges, providing commercial devices for DOD testing, and engaging nontraditional defense contractors.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Establish pilot program and scope
This subsection directs the Secretary, through the Assistant Secretary of Defense for Health Affairs, to create a pilot that assesses candidate diagnostic technologies for TBI that the Department might use in operational deployments, including combat zones. The practical implication is that the pilot’s mandate is both clinical (diagnostic accuracy and integration) and programmatic (production transition and procurement feasibility), so program design must balance lab validation, field testing, and supply-chain considerations.
Program name — Warfighter Traumatic Brain Injury Diagnostics Project
A short, named designation. Naming matters because program identity drives internal budgeting, accountability lines, and how DOD organizes reporting and stakeholder engagement; expect program offices and congressional briefings to use the name when tracking results and follow-on funding requests.
Authorized activities and study participants
The statute prescribes multi-source research studies involving DOD trauma and TBI experts, emergency medical technicians, diagnosed service members, and technology specialists. It also lets the Secretary incentivize participation from particular treatment facilities and operational units. Practically, this clause forces the pilot to run trials in realistic settings and to include end-user feedback from clinicians and affected service members—important for assessments of usability, portability, and operational utility.
Grant authority, priorities, and allowable uses
The Secretary may award grants to eligible U.S.-organized entities; priority goes to firms with prior diagnostic work, ties to the national technology and industrial base, or modular technologies. Grant funds are limited to validation testing/prototyping, addressing manufacturing/production bottlenecks, supplying devices to DOD for testing, and outreach to nontraditional defense contractors. That constrains awards to near-term development and transition activities rather than basic research, signaling the program’s focus on field-ready or close-to-market solutions.
Reporting, funding, and program end date
The Secretary must report to congressional defense committees after the pilot ends, providing results and recommendations on procurement or law changes. Congress authorized $5 million per fiscal year for FY2026–FY2029 and set the program’s termination for September 30, 2029. These budget and reporting clauses create fixed windows for evidence gathering and a cadence for congressional oversight tied to concrete funding levels.
Definitions and eligibility
The bill defines covered diagnostic technologies broadly (devices that aid in diagnosing TBI) and limits eligible grant recipients to entities organized under U.S. law or owned by such entities; it also references existing statutory meanings for civilian level-one trauma centers and nontraditional defense contractors. These definitions narrow program participants to domestically organized actors while leaving room for a wide range of diagnostic modalities to qualify.
This bill is one of many.
Codify tracks hundreds of bills on Defense across all five countries.
Explore Defense in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Service members with acute TBI exposures — stand to get earlier, more accurate point-of-injury assessment which can improve triage, immediate care decisions, and long-term prognosis.
- Military medical providers and medevac/first responders — gain validated tools and operational data to support faster, evidence-based decisions in austere or combat conditions.
- Diagnostic developers and manufacturers — receive grant funding, access to DOD test sites and user feedback, and potential pathways to DOD procurement that can de-risk private investment.
- Civilian level-one trauma centers participating in studies — get access to cutting-edge diagnostic devices and potential research collaborations that can improve civilian care pathways and translational knowledge.
- Nontraditional defense contractors and technology firms — get incentives and a formal mechanism to translate commercial diagnostic capabilities into defense-relevant solutions, which can broaden the supplier base.
Who Bears the Cost
- Department of Defense program managers and medical commands — must allocate personnel, clinical sites, and operational time to run studies and integrate new workflows, increasing internal workload without separate program offsets.
- Small diagnostic firms — face upfront costs to meet grant eligibility, participate in validation trials, and scale production; they may struggle with manufacturing or regulatory demands despite receiving grants.
- Civilian trauma centers and military treatment facilities — must commit staff and infrastructure to pilot studies, which can strain already tight clinical resources unless the Secretary’s incentives fully compensate participation costs.
- Congressional oversight and funding trade-offs — the $5 million annual authorization is modest; if oversight or additional fielding is required, future budgetary choices will impose costs elsewhere in DOD budgets.
- Regulatory and procurement processes — agencies (and acquisition offices) will face pressure to reconcile validation results with FDA-clearance requirements and standard procurement timelines, potentially stretching compliance resources.
Key Issues
The Core Tension
The bill balances two legitimate but conflicting aims: accelerate access to better, point-of-injury TBI diagnostics to protect troops and improve readiness, versus the need for rigorous clinical validation, regulatory clearance, and production scale that protect patient safety and ensure reliable performance. Moving too fast risks fielding unreliable tools; moving too slowly leaves service members without potentially lifesaving diagnostics.
Several implementation tensions could blunt the pilot’s impact. First, the authorized funding level is modest relative to the costs of multi-site clinical validation and scaling manufacturing for medical devices.
Validating clinical performance across varied deployment conditions (combat, field medics, garrison) and across diverse patient presentations will be expensive; the statute’s focus on near-term transition activities means programs may need to triage which devices receive full testing. Second, the pilot sits at the intersection of clinical validation and procurement: devices that perform well in pilot studies will still need to meet FDA regulatory standards and DOD acquisition rules before broad deployment.
Reconciling fast transition to operational use with regulatory and procurement safeguards will require clear interim policies on evidence thresholds, emergency use, and sustainment.
Data handling and privacy present a second cluster of unresolved questions. Studies will involve sensitive health and exposure data from service members; the bill does not specify data governance, retention, or secondary-use rules.
That omission raises issues for informed consent, confidentiality in the chain of command, and potential future use of data for benefit claims or research. Finally, the goal of attracting nontraditional defense contractors and broadening the industrial base competes with the reality that many commercial diagnostic firms lack experience with defense contracting, clinical trial requirements, or medical device manufacturing scale-up—meaning the pilot must include meaningful technical assistance and manufacturing support to avoid funding projects that cannot reach production.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.